Key facts
- This page summarizes Brian McKelligon's Form 4 filing for Akoya Biosciences, Inc. (AKYA).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 07 Jun 2024, 21:56.
Brian McKelligon - 06 Jun 2024 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- AKYA
- Reported as of
- 06 Jun 2024
- Net transaction value
- -$12,791
- SEC form
- 4
- Accepted by SEC
- 07 Jun 2024, 21:56:53 UTC
- Prior SEC filing
- 25 Mar 2024
- Next SEC filing
- 12 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian McKelligon
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Brian McKelligon filed Form 4 for Akoya Biosciences, Inc. (AKYA) on 07 Jun 2024.
Change
- Previous filing in this sequence was filed on 25 Mar 2024.
- Current net transaction value: -$12,791.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AKYA
transaction
Common Stock
Options Exercise
- Transaction value
- $2,272
- Shares
- +7,500
- Change %
- +3.3%
- Price
- $0.3030*
- Shares after
- 232,233
- Date
- 06 Jun 2024
- Ownership
- Direct
AKYA
transaction
Common Stock
Sale
- Transaction value
- $15,064
- Shares
- -7,500
- Change %
- -3.2%
- Price
- $2.01
- Shares after
- 224,733
- Date
- 06 Jun 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AKYA
transaction
Derivative
Employee Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -7,500
- Change %
- -2.6%
- Price
- $0.000000
- Shares after
- 283,129
- Date
- 06 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,500
- Exercise price
- $0.3030
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 3 footnotes
Footnote F1
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Brian M. McKelligon dated August 16, 2023.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.00 to $2.03, inclusive. The reporting person undertakes to provide to Akoya Biosciences, Inc., any security holder of Akoya Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
Footnote F3
The option, representing a right to purchase a total of 353,129 shares, became exercisable as follows: one-fourth of the shares vested on July 14, 2018 with the remaining shares vesting in 36 equal monthly installments beginning on August 14, 2018, subject to reporting person's continuous employment.